Skip to main content
Top
Published in: Lung 6/2014

01-12-2014

Evaluation of the Extent of Pulmonary Cysts and Their Association with Functional Variables and Serum Markers in Lymphangioleiomyomatosis (LAM)

Authors: Bruno Guedes Baldi, Mariana Sponholz Araujo, Carolina Salim Gonçalves Freitas, Gustavo Borges da Silva Teles, Ronaldo Adib Kairalla, Olívia Meira Dias, Daniel Antunes Silva Pereira, Suzana Pinheiro Pimenta, Carlos Roberto Ribeiro Carvalho

Published in: Lung | Issue 6/2014

Login to get access

Abstract

Purpose

Although computed tomography (CT) has been used previously to assess disease severity in lymphangioleiomyomatosis (LAM), the associations between the extent of pulmonary cysts on CT and six-minute walk test (6MWT), matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF-D) are not well established. We performed a cross-sectional study to quantify the extent of pulmonary cysts in CT and to establish their correlations with pulmonary function tests (PFTs), 6MWT results, including a composite index (desaturation–distance ratio, DDR), and levels of VEGF-D and MMPs in LAM.

Methods

Twenty-three LAM patients underwent CT scanning to automatically quantify the extent of pulmonary cysts and performed PFTs and 6MWT. Serum levels of MMP-2, MMP-9, and VEGF-D were also measured.

Results

The severity of pulmonary cystic involvement was mild (the extent of cysts was 6.8 %) and correlated best with FEV1/FVC (r = −0.84), residual volume (r = 0.66), DLCO (r = −0.82), the DDR index (r = 0.77), and desaturation during the 6MWT (r = −0.81). There was a weak correlation with VEGF-D (r = 0.45), but no association was found with MMP-2 and MMP-9.

Conclusions

The severity of pulmonary cystic involvement was mild in this sample of LAM patients and correlated best with airway obstruction, air trapping, reduced DLCO, the DDR index, and desaturation during the 6MWT. Serum VEGF-D cannot be completely defined as a valuable marker of disease severity and there may be a mechanism independent of MMPs to explain the formation of pulmonary cysts.
Appendix
Available only for authorised users
Literature
1.
go back to reference Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, Bonetti F, Kingswood C, Review Panel of the ERS LAM Task Force (2010) European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 35:14–26CrossRefPubMed Johnson SR, Cordier JF, Lazor R, Cottin V, Costabel U, Harari S, Reynaud-Gaubert M, Boehler A, Brauner M, Popper H, Bonetti F, Kingswood C, Review Panel of the ERS LAM Task Force (2010) European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 35:14–26CrossRefPubMed
2.
go back to reference Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL, NHLBI LAM Registry Group (2006) The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173:105–111PubMedCentralCrossRefPubMed Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, Finlay GA, Olson EJ, Ruoss SJ, Maurer JR, Raffin TA, Peavy HH, McCarthy K, Taveira-Dasilva A, McCormack FX, Avila NA, Decastro RM, Jacobs SS, Stylianou M, Fanburg BL, NHLBI LAM Registry Group (2006) The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173:105–111PubMedCentralCrossRefPubMed
3.
go back to reference Baldi BG, Albuquerque AL, Pimenta SP, Salge JM, Kairalla RA, Carvalho CR (2012) Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. Am J Respir Crit Care Med 186:341–348CrossRefPubMed Baldi BG, Albuquerque AL, Pimenta SP, Salge JM, Kairalla RA, Carvalho CR (2012) Exercise performance and dynamic hyperinflation in lymphangioleiomyomatosis. Am J Respir Crit Care Med 186:341–348CrossRefPubMed
4.
go back to reference Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J (2001) Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 164:1072–1076CrossRefPubMed Taveira-DaSilva AM, Hedin C, Stylianou MP, Travis WD, Matsui K, Ferrans VJ, Moss J (2001) Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 164:1072–1076CrossRefPubMed
5.
go back to reference Yao J, Taveira-DaSilva AM, Colby TV, Moss J (2012) CT grading of lung disease in lymphangioleiomyomatosis. AJR Am J Roentgenol 199:787–793CrossRefPubMed Yao J, Taveira-DaSilva AM, Colby TV, Moss J (2012) CT grading of lung disease in lymphangioleiomyomatosis. AJR Am J Roentgenol 199:787–793CrossRefPubMed
6.
go back to reference Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX, Dardzinski BJ, Brody AS (2009) Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in lymphangioleiomyomatosis. AJR Am J Roentgenol 192:1037–1044CrossRefPubMed Schmithorst VJ, Altes TA, Young LR, Franz DN, Bissler JJ, McCormack FX, Dardzinski BJ, Brody AS (2009) Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in lymphangioleiomyomatosis. AJR Am J Roentgenol 192:1037–1044CrossRefPubMed
7.
go back to reference Avila NA, Kelly JA, Dwyer AJ, Johnson DL, Jones EC, Moss J (2002) Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 223:189–197CrossRefPubMed Avila NA, Kelly JA, Dwyer AJ, Johnson DL, Jones EC, Moss J (2002) Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 223:189–197CrossRefPubMed
8.
go back to reference Avila NA, Chen CC, Chu SC, Wu M, Jones EC, Neumann RD, Moss J (2000) Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 214:441–446CrossRefPubMed Avila NA, Chen CC, Chu SC, Wu M, Jones EC, Neumann RD, Moss J (2000) Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 214:441–446CrossRefPubMed
9.
go back to reference Paciocco G, Uslenghi E, Bianchi A, Mazzarella G, Roviaro GC, Vecchi G, Harari S (2004) Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 125:135–142CrossRefPubMed Paciocco G, Uslenghi E, Bianchi A, Mazzarella G, Roviaro GC, Vecchi G, Harari S (2004) Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 125:135–142CrossRefPubMed
10.
go back to reference Crausman RS, Lynch DA, Mortenson RL, King TE Jr, Irvin CG, Hale VA, Newell JD Jr (1996) Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 109:131–137CrossRefPubMed Crausman RS, Lynch DA, Mortenson RL, King TE Jr, Irvin CG, Hale VA, Newell JD Jr (1996) Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 109:131–137CrossRefPubMed
11.
go back to reference Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J (2010) The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol 8:9–19PubMedCentralCrossRefPubMed Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J (2010) The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol 8:9–19PubMedCentralCrossRefPubMed
12.
go back to reference McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC, National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595–1606PubMedCentralCrossRefPubMed McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC, National Institutes of Health Rare Lung Diseases Consortium, MILES Trial Group (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364:1595–1606PubMedCentralCrossRefPubMed
13.
go back to reference Pimenta SP, Baldi BG, Kairalla RA, Carvalho CR (2013) Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. J Bras Pneumol 39:5–15PubMedCentralCrossRefPubMed Pimenta SP, Baldi BG, Kairalla RA, Carvalho CR (2013) Doxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response. J Bras Pneumol 39:5–15PubMedCentralCrossRefPubMed
14.
go back to reference Matsui K, Beasley MB, Nelson WK, Barnes PM, Bechtle J, Falk R, Ferrans VJ, Moss J, Travis WD (2001) Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 25:479–484CrossRefPubMed Matsui K, Beasley MB, Nelson WK, Barnes PM, Bechtle J, Falk R, Ferrans VJ, Moss J, Travis WD (2001) Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 25:479–484CrossRefPubMed
15.
go back to reference Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Kristof AS, Avila NA, Rabel A, Travis WD, Moss J (2003) Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 168:1427–1431CrossRefPubMed Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Kristof AS, Avila NA, Rabel A, Travis WD, Moss J (2003) Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 168:1427–1431CrossRefPubMed
16.
go back to reference Pimenta SP, Rocha RB, Baldi BG, Kawassaki AM, Kairalla RA, Carvalho CR (2010) Desaturation–distance ratio: a new concept for a functional assessment of interstitial lung diseases. Clinics 65:841–846PubMedCentralCrossRefPubMed Pimenta SP, Rocha RB, Baldi BG, Kawassaki AM, Kairalla RA, Carvalho CR (2010) Desaturation–distance ratio: a new concept for a functional assessment of interstitial lung diseases. Clinics 65:841–846PubMedCentralCrossRefPubMed
17.
go back to reference Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX (2010) Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138:674–681PubMedCentralCrossRefPubMed Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, Linehan WM, Hajjar F, Kinder BW, Trapnell BC, Bissler JJ, Franz DN, McCormack FX (2010) Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 138:674–681PubMedCentralCrossRefPubMed
18.
go back to reference Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX, MILES Trial Group (2013) Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 1:445–452PubMedCentralCrossRefPubMed Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX, MILES Trial Group (2013) Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med 1:445–452PubMedCentralCrossRefPubMed
19.
go back to reference Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, Zeng N, Gui YS, Guo Z, Feng R, Zhang W, Sun W, Cai B (2013) The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 107:263–268CrossRefPubMed Xu KF, Zhang P, Tian X, Ma A, Li X, Zhou J, Zeng N, Gui YS, Guo Z, Feng R, Zhang W, Sun W, Cai B (2013) The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med 107:263–268CrossRefPubMed
20.
go back to reference Odajima N, Betsuyaku T, Nasuhara Y, Inoue H, Seyama K, Nishimura M (2009) Matrix metalloproteinases in blood from patients with LAM. Respir Med 103:124–129CrossRefPubMed Odajima N, Betsuyaku T, Nasuhara Y, Inoue H, Seyama K, Nishimura M (2009) Matrix metalloproteinases in blood from patients with LAM. Respir Med 103:124–129CrossRefPubMed
21.
go back to reference Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD (1997) Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 28:1071–1078CrossRefPubMed Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD (1997) Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 28:1071–1078CrossRefPubMed
22.
go back to reference Pimenta SP, Baldi BG, Acencio MM, Kairalla RA, Carvalho CR (2011) Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade. J Bras Pneumol 37:424–430CrossRefPubMed Pimenta SP, Baldi BG, Acencio MM, Kairalla RA, Carvalho CR (2011) Doxycycline use in patients with lymphangioleiomyomatosis: safety and efficacy in metalloproteinase blockade. J Bras Pneumol 37:424–430CrossRefPubMed
23.
go back to reference Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319–338CrossRefPubMed Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, ATS/ERS Task Force (2005) Standardisation of spirometry. Eur Respir J 26:319–338CrossRefPubMed
24.
go back to reference Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G, ATS/ERS Task Force (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26:511–522CrossRefPubMed Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson D, Macintyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G, ATS/ERS Task Force (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26:511–522CrossRefPubMed
25.
go back to reference Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J, ATS/ERS Task Force (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735CrossRefPubMed Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J, ATS/ERS Task Force (2005) Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26:720–735CrossRefPubMed
26.
go back to reference Pereira CA, Sato T, Rodrigues SC (2007) New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol 33:397–406CrossRefPubMed Pereira CA, Sato T, Rodrigues SC (2007) New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol 33:397–406CrossRefPubMed
27.
go back to reference Neder JA, Andreoni S, Castelo-Filho A, Nery LE (1999) Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res 32:703–717PubMed Neder JA, Andreoni S, Castelo-Filho A, Nery LE (1999) Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res 32:703–717PubMed
28.
go back to reference Neder JA, Andreoni S, Peres C, Nery LE (1999) Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res 32:729–737CrossRefPubMed Neder JA, Andreoni S, Peres C, Nery LE (1999) Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res 32:729–737CrossRefPubMed
29.
go back to reference Ats A (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef Ats A (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef
30.
go back to reference Soares MR, Pereira CAC (2011) Six-minute walk test: reference values for healthy adults in Brazil. J Bras Pneumol 37:576–583CrossRef Soares MR, Pereira CAC (2011) Six-minute walk test: reference values for healthy adults in Brazil. J Bras Pneumol 37:576–583CrossRef
31.
go back to reference Tobino K, Hirai T, Johkoh T, Kurihara M, Fujimoto K, Tomiyama N, Mishima M, Takahashi K, Seyama K (2012) Differentiation between Birt–Hogg–Dubé syndrome and lymphangioleiomyomatosis: quantitative analysis of pulmonary cysts on computed tomography of the chest in 66 females. Eur J Radiol 81:1340–1346CrossRefPubMed Tobino K, Hirai T, Johkoh T, Kurihara M, Fujimoto K, Tomiyama N, Mishima M, Takahashi K, Seyama K (2012) Differentiation between Birt–Hogg–Dubé syndrome and lymphangioleiomyomatosis: quantitative analysis of pulmonary cysts on computed tomography of the chest in 66 females. Eur J Radiol 81:1340–1346CrossRefPubMed
Metadata
Title
Evaluation of the Extent of Pulmonary Cysts and Their Association with Functional Variables and Serum Markers in Lymphangioleiomyomatosis (LAM)
Authors
Bruno Guedes Baldi
Mariana Sponholz Araujo
Carolina Salim Gonçalves Freitas
Gustavo Borges da Silva Teles
Ronaldo Adib Kairalla
Olívia Meira Dias
Daniel Antunes Silva Pereira
Suzana Pinheiro Pimenta
Carlos Roberto Ribeiro Carvalho
Publication date
01-12-2014
Publisher
Springer US
Published in
Lung / Issue 6/2014
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-014-9641-2

Other articles of this Issue 6/2014

Lung 6/2014 Go to the issue